Antioxidant capacity in rat brain after ICV treatment with streptozotocin and alloxan - A preliminary study

Neurotoxicity Research

Volumn 13, Issue 2, 2008, Pages 97-104

  Sapcanin, A ^a   Sofic, E ^a   Tahirovic, I ^a   Salkovic Petrisic, M ^b   Hoyer, S ^c   Riederer, P ^d  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Alloxan; Alzheimer's disease; Antioxidant capacity; Hydroxyl radical; Oxidative stress; Oxygen radical absorbance capacity (ORAC) assay; Peroxyl radical; Streptozotocin

Indexed keywords

3 METHYLGLUCOSE; ALLOXAN; HYDROXYL RADICAL; STREPTOZOCIN; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT; GLUCOSE TRANSPORTER 2; SLC2A2 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG RESEARCH; FRONTAL CORTEX; MALE; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PARIETAL LOBE; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DRUG ANTAGONISM; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MAZE TEST; METABOLISM; OXIDATIVE STRESS; WISTAR RAT;

RATTUS;

ALLOXAN; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; BRAIN; COGNITION DISORDERS; GLUCOSE TRANSPORTER TYPE 2; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; OXIDATIVE STRESS; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 49849088654     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033561     Document Type: Article

References (42)

1. Anger WK (1991) Animal test systems to study behavioral dysfunctions ofneurodegenerative disorders. Neurotoxicology 12, 403-413.
2. Calabrese V, G Scapagnini, C Colombrita, A Ravagna, G Pennisi, AM Giuffrida Stella, F Galli and DA Butterfield (2003) Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: A nutritional approach. Amino Acids 25, 437-444.
3. Cao G, HM Alessio and RG Cutler (1993) Oxygen-radical absorbance capacity assay for antioxidants. Free Radic. Biol. Med. 14, 303-311.
4. Cao G, C Verdon, AHB Wu, H Wang and RL Prior (1995) Automated oxygen radical absorbance capacity assay using the COBAS FARAII. Clin. Chem. 41, 1738-1744.
5. Cao G, E Sofic and R Prior (1996a) Antioxidant capacity of tea and common vegetables. J. Agric. Food Chem. 44, 3426-3431.
6. Cao G, M Giovanoni and R Prior (1996b) Antioxidant capacity decreases during growth but not aging in rat serum and brain. Arch. Gerontol. Geriatr. 22, 27-37.
7. Cao G, M Giovanoni and R Prior (1996c) Antioxidant capacity in different tissues of young and old rats. Proc. Soc. Exp. Biol. Med. 211, 359-365.
8. Cao G, E Sofic and R Prior (1997) Antioxidant and prooxidant behavior of flavonoids: Structure-activity relationships. Free Radic. Biol. Med. 22, 749-760.
9. Crino PB, D Ullman, BA Vogt, ED Bird and L Volicer (1989) Brain gangliosides in dementia of the Alzheimer type. Arch. Neurol. 46, 398-401.
10. Ding A, R Nitsch and S Hoyer (1992) Changes in brain monoaminergic neurotransmitter concentrations in rat after intracerebroventricular injections of streptozotocin. J. Cereb. Blood Flow Metab. 12, 103-109.
11. Flirski M and T Sobow (2005) Biochemical markers and risk factors of Alzheimer's disease. Curr. Alzheimer Res. 2(1), 47-64.
12. Giasson B, H Ischiropoulos, V Lee and J Trojanowski (2002) The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic. Biol. Med. 32(12), 1264-1275.
13. Götz M, A Freyberger, E Hauer, R Burger, S Heckers, E Sofic, K Jellinger, G Hebenstreit, H Beckmann and P Riederer (1992) Susceptibility to brains from patients with Alzheimer's disease to oxygen-stimulated lipid peroxidation and differential scanning calorimetry. Dementia 3, 213-222.
14. Grünblatt E, M Salkovic-Petrisic, J Osmanovic, P Riederer and S Hoyer (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J. Neurochem. 101(3), 757-770.
15. Ishrat T, MB Khan, MN Hoda, S Yousuf, M Ahmad, MA Ansari, AS Ahmad and F Islam (2006) Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. Behav. Brain Res. 171, 9-16.
16. Lackovic Z and M Šalkovic (1990) Streptozocin and alloxan produce alterations in rat brain monoamines independently of pancreatic beta cells destruction. Life Sci. 46, 49-54.
17. Lannert H and S Hoyer (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 112, 1199-1208.
18. Mandel S, T Amit, L Reznichenko, O Weinreb and MB Youdim (2006) Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol. Nutr. Food Res. 50, 229-234.
19. Mariani E, MC Polidori, A Cherubini and P Mecocci (2005) Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 827, 65-75.
20. McEwen BS and LP Reagan (2004) Glucose transporter expression in the central nervous system: Relationship to synaptic function. Eur. J. Pharmacol. 490, 13-24.
21. Montine TJ, JF Quinn, KS Montine, JA Kaye and JC Breitner (2005) Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. J. Alzheimers Dis. 8(4), 359-367.
22. 3-norepinephrine into the lateral ventricle ofthe rat brain. Life Sci. 6, 281-291.
23. Pappoila MA, YJ Chyan, RA Qrer, K Hsiao, G Perry, MA Smith et al. (1998) Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 152, 871-877.
24. Pathan AR, B Viswanad, SK Sonkusare and P Ramarao (2006) Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 79, 2209-22016.
25. Pratico D (2002) Alzheimer's disease and oxygen radicals: New insights. Biochem. Pharmacol. 63, 563-567.
26. Pratico D and S Sung (2003) Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J. Alzheimers Dis.6 (2), 171-175.
27. Prickaerts J, T Fahring and A Blokland (1999) Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v. injection of streptozotocin: A correlation analysis. Behav. Brain Res. 102, 73-88.
28. Prickaerts J, J De Vente, W Honig, H Steinbusch, MMV Ittersum, A Blokland and HW Steinbusch (2000) Nitric oxide synthase does not mediate neurotoxicity after an i.c.v. injection of streptozotocin in the rat. J. Neural Transm. 107, 745-766.
29. Prior RL, H Hoang, L Gu, X Wu, M Bacchiocca, L Howard, M Hampsch-Woodill, D Huang, B Ou and R Jacob (2003) Assays for hydrophilic and lipophilic antioxidant capacity [oxygen radical absorbance capacity (ORAC-FL)] of plasma and other biological and food samples. J. Agric. Food Chem. 51, 3273-3279.
30. Salkovic-Petrisic M and Z Lackovic (2003) Intracerebroventricular administration of betacytotoxics alters expression of brain monoamine transporter genes. J. Neural Transm. 110, 15-29.
31. Salkovic-Petrisic M, F Tribil, M Schmidt, S Hoyer and P Riederer (2006) Alzheimer-like changes of protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J. Neurochem. 96, 1005-1015.
32. Sapcanin A, I Tahirovic, K Kalcher and E Sofic (2005) Antioxidant capacity declined during growth but not in aging in mouse brain [Abstr.]. Parkinsonism Relat. Disord. 11 [Suppl. 2], 159.
33. Sharma M and YK Gupta (2001a) Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci. 68, 1021-1029.
34. Sharma M and YK Gupta (2001b) Effect of chronic treatment of melatoninon learning, memory and oxidative deficiencies induced by intracerebroventricular streptozotocin in rats. Pharmacol. Biochem. Behav. 70, 325-331.
35. Sharma M and YK Gupta (2002) Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci. 71, 2489-2498.
36. Sofic E, A Rustembegovic, G Kroyer and G Cao (2002) Serum antioxidant capacity in neurological, psychiatric, renal diseases and cardiomyopathy. J. Neural Transm. 109, 711-719.
37. Sofic E, A Sapcanin, I Tahirovic, K Jellinger, GP Reynolds, T Tatschner and P Riederer (2006) Antioxidant capacity in the postmortem brain tissues of Parkinson's disease and Alzheimer's disease, In: Oxidative Stress and Neuroprotection (Parvez H and P Riederer, Eds.) (Springer:WIen, New York), J. Neural Transm. Suppl. 71, pp 39-43.
38. Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 50, 537-546.
39. Tahirovic I, E Sofic, A Sapcanin, I Gavrankapetanovic, L Bach-Rojecky, M Salkovic-Petrisic, Z Lackovic, S Hoyer and P Riederer (2007a) Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus, In: Neuropsychiatric Disorders: An Integrative Approach (Gerlach M et al., Eds.) (Springer:WIen, New York), J. Neural Transm. Suppl. 72 (in press).
40. Tahirovic I, E Sofic, A Sapcanin, I Gavrankapetanovic, L Bach-Rojecky, M Salkovic-Petrisic, Z Lackovic, S Hoyer and P Riederer (2007b) Reduced brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus. Neurochem. Res. 2007 Jun 29; [Epub ahead of print].
41. Wang CC, CY Chu, KO Chy, KW Choy, KS Khaw, MS Rogers and CP Pang (2004) Trolox equivalent antioxidant capacity assay versus oxygen radical absorbance capacity assay in plasma. Clin. Chem. 50, 952-954.
42. Yamada K and T Nabeshima (2000) Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol. Ther. 88(2), 93-113.